Infectious diseases continue to affect and kill a multitude of people worldwide, with vaccination seen as the most powerful weapon against this threat. Vaccines are prepared from weakened forms of the agent, its toxins, or its surface proteins. The vaccine stimulates the immune system into recognizing the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with this agent in the future. However, identifying the peptide sequences which trigger this protective immune response and to manufacture synthetic versions of these as the vaccine would be a desirable alternative. Theoretically, this would mean there would be less risk of mutation or reversion, less risk of contamination by pathogenic or toxic substances, and chemical manipulation of the peptide structure could possibly increase thermostability and decrease side effects. Now, a study led by researchers at the University of Bristol develops a synthetic vaccine that can be stored at warmer temperatures, removing the need for refrigeration. The team states their vaccine, developed for the mosquito-borne virus Chikungunya, was engineered using a synthetic protein scaffold with the potential revolutionize the way vaccines are designed, produced and stored. The opensource study is published in the journal Science Advances.
Previous studies show it is hoped due to the ease in sequencing new strains and serotypes of microorganisms, synthetic vaccines could be rapidly modified to generate strain-specific responses. However, the approach is not without difficulties as often the antigen epitope, a region on the surface of an antigen capable of eliciting an immune response, is composed of various parts of the protein sequence coming together to build a three-dimensional structure. Therefore, the modeling of these structures will be needed to generate the correct antigenic site synthetically. The current study uses Oracle’s cloud infrastructure to model and develop a self-assembling protein-based scaffold engineered to facilitate multiple antigenic epitopes.
The current study develops a protein yielding a multimeric particle resembling a virus containing no genetic material inside, rendering it completely safe. Results show the particle is incredibly stable even after months, without refrigeration, and is easy to modify and produce in high yields. Data findings show the particle can accommodate hundreds of epitopes, same or different, providing vast opportunity to fight multiple diseases in one sitting.
The lab states their vaccine candidate is easy to manufacture, extremely stable and elicits a powerful immune response. They go on to add it can be stored and transported without refrigeration to countries and patients where it is needed most. They conclude a wide range of applications in biomedical research will benefit from this exceptionally versatile multiple epitope platform.
The team surmises they have developed a self-assembling, multiple epitope synthetic vaccine system stored at warmer temperatures. For the future, the researchers state their synthetic vaccine exhibited promising results in animal studies, setting the stage for a future vaccine to combat Chikungunya disease.
Source: University of Bristol
Get Healthinnovations delivered to your inbox:
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.